New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
10:11 EDTSQM, NVO, RDY, WAG, SBGL, NMR, DCIX, TNK, GOLD, NIHDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Diana Containerships (DCIX) downgraded to Neutral from Buy at Euro Pacific Capital... Dr. Reddy's Labs (RDY) downgraded to Underperform from Buy at BofA/Merrill... NII Holdings (NIHD) downgraded to Sell from Hold at Gabelli... Nomura (NMR) downgraded to Neutral from Outperform at Credit Suisse... Novo Nordisk (NVO) downgraded to Neutral from Buy at UBS... Randgold Resources (GOLD) downgraded to Neutral from Overweight at JPMorgan... Sibanye Gold (SBGL) downgraded to Neutral from Overweight at JPMorgan... Sociedad Quimica (SQM) downgraded to Underperform from Neutral at Credit Suisse... Teekay Tankers (TNK) downgraded at BofA/Merrill... Walgreens (WAG) downgraded to Market Perform from Outperform at Cowen.
News For DCIX;RDY;NIHD;NMR;NVO;GOLD;SBGL;SQM;TNK;WAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
10:00 EDTGOLDRandgold upgraded to Buy from Neutral at UBS (pre-open)
Subscribe for More Information
April 15, 2015
11:55 EDTNVONovo Nordisk initiated with a Sell at Societe Generale
Subscribe for More Information
07:41 EDTNVOEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 13, 2015
10:00 EDTSBGLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:38 EDTSBGLSibanye Gold upgraded to Neutral from Sell at Citigroup
Subscribe for More Information
April 10, 2015
06:19 EDTNMRNomura, RBS accused of 'deceit' and incompetence' in trial, Financial Times says
Subscribe for More Information
April 9, 2015
06:57 EDTDCIXDiana Containerships announces delivery of Panamax container vessel
Subscribe for More Information
April 8, 2015
12:17 EDTRDYOn The Fly: Midday Wrap
Subscribe for More Information
05:10 EDTRDYDr. Reddy's Labs files three NDAs with FDA
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, announced the filing of three 505(b)(2) New Drug Applications, or NDAs, with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology and neurology. DFD-01 and DFD-09 are the first dermatology applications submitted to the NDA that have been fully developed leveraging in-house capabilities. DFD-01 is a corticosteroid delivered in a novel non-irritating spray platform, intended for the treatment of patients suffering from psoriasis. DFD-09 is a modified release oral tetracycline intended for the treatment of rosacea. DFN-11 is the first development program filed in support of a newly created vertical, focused on the U.S. neurology market. DFN-11 is a drug-device combination product intended to treat acute migraine episodes in certain patient populations who are inadequately managed with existing treatment regimens.
April 7, 2015
15:44 EDTNVONovo Nordisk announces FDA accepts Tresiba, Ryzodeg resubmissions for review
Novo Nordisk announced that the U.S. FDA has accepted for review the Class II Resubmissions for Tresiba and Ryzodeg. To preserve the integrity of the ongoing DEVOTE trial, only a small team within Novo Nordisk has access to the data. This team has prepared the interim analysis for the Class II resubmission and will interact with the FDA during the review, on matters related to the interim analysis. As previously communicated, the result of an interim analysis carries a higher level of uncertainty than the final study results as this preliminary estimate is built on a substantially lower number of observations. Accordingly, the relative risk estimate derived from the interim analysis is thus only an indication of the final trial results. Novo Nordisk management does not have access to the results of the interim analysis. The trial is expected to be completed in the second half of 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use